Asimov and Lotte Biologics Collaborate to Accelerate GMP Manufacturing

Synthetic biology company, Asimov, and Korean manufacturer, Lotte Biologics, have formed a partnership to streamline the transition from cell line development to large-scale GMP production. This collaboration integrates Asimov's CHO Edge platform - known for generating high-titer, stable cell lines - with Lotte Biologics' extensive manufacturing capabilities.

The CHO Edge system utilizes a GS (glutamine synthetase) knock-out CHO host, a hyperactive transposase, advanced computational tools, and a library of over 1,000 characterized genetic elements to optimize expression vectors and bioreactor processes across various biologic modalities. The partnership aims to enhance efficiency and speed in biologics development, offering clients a more streamlined pathway from initial development to commercial-scale manufacturing.

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, and LOTTE BIOLOGICS, a global CDMO, today announced a strategic partnership focused on accelerating cell line development and scaling to GMP manufacturing, having demonstrated successful scale-up.

This collaboration combines Asimov's advanced CHO Edge cell line development platform with LOTTE BIOLOGICS' robust large-scale manufacturing services, significantly increasing efficiency and speed from development to production for therapeutic developers.

Alec Nielsen, Asimov co-founder and CEO, said: “We’re delighted to be directly integrating with LOTTE BIOLOGICS’ established manufacturing capabilities, meaning our customers can now transition seamlessly from cell line development to large-scale GMP production, and drastically shorten their development cycles.”

James Park, LOTTE BIOLOGICS CEO, commented: “We believe this agreement will unlock the full potential of both companies’ strengths. By combining Asimov’s cutting-edge technology with LOTTE BIOLOGICS’ manufacturing excellence, we will not only deliver unparalleled services to our customers but also drive innovation in the biopharmaceutical industry. Ultimately, our goal is to make a meaningful impact on patients’ lives, and we will continue striving to be a company that contributes to a healthier future for all.”

For more, please find the original story source here.